IP Library › Granted Patent US 12,357,799
Granted Patent B2
US 12,357,799 · App. 18/170,456 · Granted Jul 15, 2025

Systems and methods for selectively occluding the superior vena cava for treating heart conditions

Inventors: Navin K. Kapur (Hanover, MA); Richard Karas (Franklin, MA)
Assignee: Tufts Medical Center, Inc.
A61M25/10184A61B5/02028A61B5/02152A61B5/02444A61B5/026A61B5/027A61B5/6853A61B17/12036A61B17/1204A61B17/12109A61B17/12136A61B17/12172A61B17/1322A61B17/1355A61B2017/00022A61B2017/00044A61B2017/00221A61B2017/00398A61B2017/00734A61B2017/00889A61B2090/065A61B2562/0247A61M2025/1052A61M2205/3331A61M2230/005A61M2230/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,357,799
App. No.
18/170,456
Granted
Jul 15, 2025
Kind
B2
Abstract

Systems and methods and devices are provided for treating conditions such as heart failure and/or pulmonary hypertension by at least partially occluding flow through the superior vena cava for an interval spanning multiple cardiac cycles. A catheter with an occlusion device is provided along with a controller that actuates a drive mechanism to provide at least partial occlusion of the patient's superior vena cava, which reduces cardiac filling pressures, and induces a favorable shift in the patient's Frank-Starling curve towards healthy heart functionality and improved cardiac performance. The occlusion device may include a lumen obstructed by a relief valve that may permit fluid flow through the occlusion device to release an excessive build-up of pressure.

Claims (36)

1. A system for unloading of cardiac preload and afterload, the system comprising:

a cardiac assist device configured to pump blood within a patient to reduce cardiac afterload;

a flow limiting element configured to be positioned at a superior vena cava (SVC) of the patient; and

a controller configured to be coupled to the flow limiting element, the controller configured to cause the flow limiting element to fully occlude the SVC over multiple cardiac cycles to reduce cardiac preload.

2. The system of claim 1 , wherein the flow limiting element is disposed on a catheter configured to be intravascularly positioned within the SVC, and

wherein the controller is configured to fully occlude the SVC by expanding the flow limiting element.

3. The system of claim 1 , wherein the controller is configured to cause the flow limiting element to expand and contract within the SVC to reduce the cardiac preload.

4. The system of claim 3 , wherein the controller is configured to cause the flow limiting element to repeat the expansion and the contraction over a course of a treatment.

5. The system of claim 4 , wherein the controller is configured to cause the flow limiting element to expand to fully occlude the SVC for a first predetermined time interval and to contract for a second predetermined time interval over multiple cardiac cycles.

6. The system of claim 5 , wherein the first predetermined time interval is at least five times greater than the second predetermined time interval.

7. The system of claim 5 , wherein the first predetermined time interval is 5-20 minutes and the second predetermined time interval is 10-100 seconds.

8. The system of claim 1 , wherein the controller is configured to cause the flow limiting element to fully occlude the SVC for more than a minute during expansion.

9. The system of claim 1 , wherein the cardiac assist device comprises a catheter.

10. The system of claim 9 , wherein the cardiac assist device comprises an impeller pump disposed at a distal portion of the catheter.

11. The system of claim 9 , wherein the cardiac assist device is a left ventricular assist device (LVAD).

12. The system of claim 1 , wherein the cardiac assist device is a percutaneous left ventricular assist device (LVAD).

13. The system of claim 1 , wherein the cardiac assist device is an intra-aortic balloon pump (IABP).

14. The system of claim 1 , wherein the controller is configured to cause the flow limiting element to fully occlude the SVC to reduce the patient's diastolic volume and improve cardiac performance as measured by at least one of: reduced cardiac filling pressures, increased left ventricular relaxation, increased left ventricular capacitance, increased left ventricular stroke volume, increased lusitropy, reduced left ventricular stiffness or reduced cardiac strain.

15. The system of claim 1 , wherein the controller is configured to cause the flow limiting element to fully occlude the SVC to create a negative pressure sink in a right atrium of the patient, accelerating flow from a renal vein, thereby enhancing renal decongestion and promoting blood flow across a kidney of the patient.

16. The system of claim 1 , further comprising a sensor for monitoring pressure differential across the flow limiting element in the SVC indicative of an amount or degree of occlusion in the SVC.

17. The system of claim 1 , further comprising:

a first pressure sensor disposed proximal to the flow limiting element, the first pressure sensor configured to output a first pressure signal; and

a second pressure sensor disposed distal to the flow limiting element, the second pressure sensor configured to output a second pressure signal,

wherein the controller is configured to determine pressure in the SVC based on the first pressure signal or the second pressure signal or both.

18. The system of claim 1 , wherein the cardiac assist device and the flow limiting element utilize coaxial catheters.

19. The system of claim 1 , further comprising a sensor configured to generate a signal corresponding to a physiologic parameter indicative of the patient's hemodynamic state,

wherein the controller is configured to permit adjustment of actuation of the flow limiting element responsive to the signal.

20. The system of claim 1 , wherein the flow limiting element is a balloon.

21. A system for unloading of cardiac preload and afterload, the system comprising:

a percutaneous heart pump configured to pump blood within a patient to reduce cardiac afterload;

a balloon catheter configured to be positioned within a superior vena cava (SVC) of the patient; and

a controller configured to be coupled to the balloon catheter, the controller configured to cause a balloon of the balloon catheter to expand to fully occlude the SVC over multiple cardiac cycles to reduce cardiac preload.

22. The system of claim 21 , wherein the controller is configured to cause the balloon to expand and contract within the SVC over a course of a treatment to reduce the cardiac preload.

23. The system of claim 22 , wherein the controller is configured to cause the balloon to expand to fully occlude the SVC for a first predetermined time interval and to contract for a second predetermined time interval over multiple cardiac cycles.

24. The system of claim 23 , wherein the first predetermined time interval is at least five times greater than the second predetermined time interval.

25. The system of claim 24 , wherein the first predetermined time interval is 5-20 minutes and the second predetermined time interval is 10-100 seconds.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 16, 2023
From: KAPUR, NAVIN K.; KARAS, RICHARD H.
To: TUFTS MEDICAL CENTER, INC.
Reel/Frame 062726/0496 →
Continuity (8)
Continuation 17100680 · Nov 20, 2020
Continuation 16168357 · Oct 23, 2018
Continuation In Part 15753300
Continuation In Part 15203437 · Jul 6, 2016
Continuation 14828429 · Aug 17, 2015
Provisional Application 62642569 · Mar 13, 2018
Provisional Application 62576529 · Oct 24, 2017
Related Publication 20230241361A1 · Aug 3, 2023
References Cited (113)
US 4546759A · Solar · 1985 [cited by applicant]
US 4576181A · Wallace et al. · 1986 [cited by applicant]
US 4610256A · Wallace · 1986 [cited by applicant]
US 4846787A · Aall-Flood et al. · 1989 [cited by applicant]
US 4949723A · Wallace et al. · 1990 [cited by applicant]
US 5021046A · Wallace · 1991 [cited by applicant]
US 5097840A · Wallace et al. · 1992 [cited by applicant]
US 5330451A · Gabbay · 1994 [cited by applicant]
US 5458574A · Machold et al. · 1995 [cited by applicant]
US 6146354A · Beil · 2000 [cited by applicant]
US 6485500B1 · Kokish et al. · 2002 [cited by applicant]
US 6726651B1 · Robinson et al. · 2004 [cited by applicant]
US 6790043B2 · Aboud · 2004 [cited by applicant]
US 6843779B1 · Andrysiak et al. · 2005 [cited by applicant]
US 7476200B2 · Tal · 2009 [cited by applicant]
US 7896840B2 · Spencer et al. · 2011 [cited by applicant]
US 7909794B2 · Briscoe et al. · 2011 [cited by applicant]
US 7909844B2 · Alkhatib et al. · 2011 [cited by applicant]
US 7914643B2 · Simpson · 2011 [cited by applicant]
US 7951259B2 · Duchamp et al. · 2011 [cited by applicant]
US 7959667B2 · Ta et al. · 2011 [cited by applicant]
US 7967781B2 · Simpson et al. · 2011 [cited by applicant]
US 7972299B2 · Carter et al. · 2011 [cited by applicant]
US 8449565B2 · Duhay · 2013 [cited by applicant]
US 8646325B2 · Hoem et al. · 2014 [cited by applicant]
US 8679052B2 · Bellantone · 2014 [cited by applicant]
US 8876850B1 · Vollmers et al. · 2014 [cited by applicant]
US 8968239B2 · Herrera · 2015 [cited by applicant]
US 9393384B1 · Kapur et al. · 2016 [cited by applicant]
US 9878080B2 · Kaiser et al. · 2018 [cited by applicant]
US 9901722B2 · Nitzan et al. · 2018 [cited by applicant]
US 10279152B2 · Kapur et al. · 2019 [cited by applicant]
US 10639460B2 · Nitzan et al. · 2020 [cited by applicant]
US 10653871B2 · Nitzan et al. · 2020 [cited by applicant]
US 10758715B2 · Kapur et al. · 2020 [cited by applicant]
US 10842974B2 · Kapur et al. · 2020 [cited by applicant]
US 10926069B2 · Nitzan et al. · 2021 [cited by applicant]
US 11872361B2 · Kapur et al. · 2024 [cited by applicant]
US 20030186203A1 · Aboud · 2003 [cited by applicant]
US 20040022640A1 · Siess et al. · 2004 [cited by applicant]
US 20040064090A1 · Keren et al. · 2004 [cited by applicant]
US 20040167376A1 · Peters et al. · 2004 [cited by applicant]
US 20050015048A1 · Chiu et al. · 2005 [cited by applicant]
US 20060064059A1 · Gelfand et al. · 2006 [cited by applicant]
US 20060206029A1 · Yair · 2006 [cited by applicant]
US 20080294070A1 · Kinori · 2008 [cited by applicant]
US 20090131785A1 · Lee et al. · 2009 [cited by applicant]
US 20100318114A1 · Pranevicius et al. · 2010 [cited by applicant]
US 20100331876A1 · Cedeno · 2010 [cited by applicant]
US 20110202084A1 · Hoem et al. · 2011 [cited by applicant]
US 20110282274A1 · Fulton, III · 2011 [cited by applicant]
US 20110295177A1 · Mohl · 2011 [cited by applicant]
US 20110295302A1 · Mohl · 2011 [cited by applicant]
US 20120029466A1 · Callaghan et al. · 2012 [cited by applicant]
US 20130023909A1 · Duhay · 2013 [cited by applicant]
US 20150201944A1 · Starnes · 2015 [cited by applicant]
US 20150223707A1 · Ludoph · 2015 [cited by applicant]
US 20170049946A1 · Kapur et al. · 2017 [cited by applicant]
US 20180000488A1 · Hu et al. · 2018 [cited by applicant]
US 20180243541A1 · Kapur et al. · 2018 [cited by applicant]
US 20190070348A1 · Frost · 2019 [cited by applicant]
US 20190126014A1 · Kapur et al. · 2019 [cited by applicant]
US 20190255302A1 · Kapur et al. · 2019 [cited by applicant]
US 20200038566A1 · Johnson et al. · 2020 [cited by applicant]
US 20210077792A1 · Kapur et al. · 2021 [cited by applicant]
US 20220104828A1 · Keating et al. · 2022 [cited by applicant]
CN 1819855A · 2006 [cited by applicant]
EP 2353501A1 · 2011 [cited by applicant]
EP 2353503A1 · 2011 [cited by applicant]
WO WO9300037A1 · 1993 [cited by applicant]
WO WO2004073796A2 · 2004 [cited by applicant]
WO WO2013061281A1 · 2013 [cited by applicant]
WO WO2015009028A1 · 2015 [cited by applicant]
WO WO2015109028A1 · 2015 [cited by applicant]
WO WO2017031068A1 · 2017 [cited by applicant]
WO WO2017081561A1 · 2017 [cited by applicant]
WO WO2019083989A1 · 2019 [cited by applicant]
WO WO2019140073A1 · 2019 [cited by applicant]
WO WO2020061143A1 · 2020 [cited by applicant]
WO WO2020097428A1 · 2020 [cited by applicant]
Atherton, et al., Diastolic Ventricular Interaction In Chronic Heart Failure, Lancet, 349(9067):1720-1724 (1997). [cited by applicant]
Bannon, et al., Anatomic Considerations for Central Venous Cannulation, 4 Risk Management and Healthcare Policy, 4:27-39 (2011). [cited by applicant]
Bilecen, et al., MR Angiography With Venous Compression, Radiology, 233(2):617-619 (Nov. 2004). [cited by applicant]
Delis, et al., Effect of Posture on Popliteal Artery Hemodynamics, 135(3):265-269 (Mar. 2000). [cited by applicant]
Difference Between Superior and Inferior Vena Cava, Pediaa (Aug. 28, 2018), https://pediaa.com/difference-between-superior-and-inferior-vena-cava/. [cited by applicant]
Extended EP Search Report dated Oct. 20, 2021 in EP Patent Application Serial No. 21177661.2. [cited by applicant]
Hansen, et al., Veno-occlusive unloading of the heart reduces infarct size in experimental ischemia-reperfusion, [cited by applicant]
Herrera, et al., First Percutaneous Transluminal Caval Flow Restriction in a Patient With Congestive Heart Failure, Abstract No. TCT-428, New Devices and Innovation, www.jacctctabstracts 2014.com, vol. 64/11/Suppl B, Se… [cited by applicant]
International Search Report & Written Opinion dated Jan. 28, 2019 in Int'l PCT Patent Appl. Serial No. PCT/US2018/057085. [cited by applicant]
International Search Report & Written Opinion dated Feb. 18, 2021 in Int'l PCT Patent Appl. Serial No. PCT/US2020/061386. [cited by applicant]
International Search Report & Written Opinion dated Oct. 18, 2016 in Int'l PCT Patent Application Serial No. PCT/US2016/047055. [cited by applicant]
Ishiguchi, et al., Endovascular Stent-Graft Deployment: Temporary Vena Caval Occlusion with Balloons to Control Aortic Blood Flow-Experimental Canine Study and Initial Clinical Experience, Radiology, 215:(2):594-599 (20… [cited by applicant]
Kaiser, et al., First-in-Human Experience of Mechanical Preload Control in Patients With HFpEF During Exercise, [cited by applicant]
Kappagoda, et al., Effect of Stimulating Right Atrial Receptors On Urine Floe In The Dog, J. Physiol, 235:493-502 (1973). [cited by applicant]
Kapur, et al., First-in-human experience with occlusion of the superior vena cava to reduce cardiac filling pressures in congestive heart failure, Catheter Cardiovasc. Interv., 93:1205-1210 (2019). [cited by applicant]
Kapur, et al., Intermittent Occlusion of the Superior Vena Cava Reduces Cardiac Filling Pressures in Preclinical Models of Heart Failure, Journal of Cardiovascular Translational Research, published on: Nov. 26, 2019, ht… [cited by applicant]
Kass, et al., Use of a conductance (volume) catheter and transient inferior vena caval occlusion for rapid determination of pressure-volume relationships in man, Cathet. Cardiovasc. Diagn., 15(3):192-202 (1988). [cited by applicant]
Lee et al., Partial right atrial inflow occlusion for controlled systemic hypotension during thoracic endovascular aortic repair, [cited by applicant]
Low, Phillip A., “Venoarteriolar Reflex,” Primer On The Autonomic Nervous System, Second Edition, Chapter 38, pp. 152-153 (2004). [cited by applicant]
Mehta, M.D., Manish, Compliant Occlusion Balloons—Use of complaint occlusion balloons during EVAR for AAA rupture, insert to [cited by applicant]
Mork, et al., Impaired Neurogenic Control of Skin Perfusion In Erythromelalgia, Journal of Investigative Dermatology, 118(4):699-703 (Apr. 2002). [cited by applicant]
Moscucci, M., Grossman & Baim's Cardiac Catheterization, Angiography, and Intervention, 8th Edition, 2014. [cited by applicant]
Rachapalli, et al., Superior Vena Cava Syndrome: Role of the Interventionalist, Canadian Association of Radiologists Journal, 65:168-176 (2014). [cited by applicant]
Rodrigues, et al., Effect of baroreceptor denervation on the autonomic control of arterial pressure in conscious mice, [cited by applicant]
Rosenblum, et al., Conceptual Considerations For Device-Based Therapy in Acute Decompensated Heart Failure, [cited by applicant]
Ross, et al., Studies on Starling's Law of the Heart, IX. The Effects of Impeding Venous Return on Performance of the Normal and Failing Human Left Ventricle, [cited by applicant]
Shimizu, et al., Embolization of a Fractured Central Venous Catheter Placed Using The Internal Jugular Approach, International Journal of Surgery Case Reports, 5(5):219-221 (Jan. 2014). [cited by applicant]
Swan, et al., Catheterization Of The Heart In Man With Use Of A Flow-Directed Balloon-Tipped Catheter, New England Journal of Medicine, 283(9):447-451 (Aug. 1970). [cited by applicant]
Tucker, et al., Anatomy, Abdomen and Pelvis, Inferior Vena Cava, Jul. 27, 2021, available at https://www.ncbi.nlm.nih.gov/books/NBK482353/. [cited by applicant]
Tzifa, et al., Endovascular Treatment for Superior Vena Cava Occlusion or Obstruction in a Pediatric and Young Adult Population, A 22-Year Experience, Journal of the American College of Cardiology, 49(9):1003-1009 (2007… [cited by applicant]
Van Fossen, et al., Safety and efficacy of inferior vena caval occlusion to rapidly alter ventricular loading conditions in idiopathic dilated cardiomyopathy, The American Journal of Cardiology, 59(9):937-942 (1987). [cited by applicant]
Yancy, et al., 2013 ACCF/AHA Guideline for the Management of Heart Failure-A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, Circulation, 128:e240-e3… [cited by applicant]
International Search Report & Written Opinion dated Aug. 23, 2023 in Int'l PCT Patent Appl. Serial No. PCT/US2023/024440. [cited by applicant]
Cited By (1)
US 12,708,370